




PHARMACEUTICAL 2022

Arcus Biosciences Inc.
Rank 225 of 466





RealRate

PHARMACEUTICAL 2022

Arcus Biosciences Inc.
Rank 225 of 466



The relative strengths and weaknesses of Arcus Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcus Biosciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Arcus Biosciences Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 120% points.

The company's Economic Capital Ratio, given in the ranking table, is 128%, being 50% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	1,261,750
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	166,084
Liabilities, Non-Current	584,364
Other Assets	297,693
Other Compr. Net Income	-1,305
Other Expenses	1,815
Other Liabilities	0
Other Net Income	397
Other Revenues	382,882
Property and Equipment	32,455
Research and Development	256,348
Selling, General and Administrative Expense	72,286

Output Variable	Value in 1000 USD
Assets	1,591,898
Liabilities	750,448
Expenses	330,449
Revenues	382,882
Stockholders Equity	841,450
Net Income	52,830
Comprehensive Net Income	52,178
Economic Capital Ratio	128%